Cargando…

Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency

Oncolytic virus (OV) therapy has emerged as a promising approach for cancer treatment with the potential to be less toxic and more efficient than classic cancer therapies. Various types of OVs in clinical development, including Vaccinia virus (VACV)-derived OVs, have shown good safety profiles, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ricordel, Marine, Foloppe, Johann, Antoine, Delphine, Findeli, Annie, Kempf, Juliette, Cordier, Pascale, Gerbaud, Aude, Grellier, Benoit, Lusky, Monika, Quemeneur, Eric, Erbs, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070928/ https://www.ncbi.nlm.nih.gov/pubmed/29996551 http://dx.doi.org/10.3390/cancers10070231

Ejemplares similares

Oncolytic properties of non-vaccinia poxviruses
por: Ricordel, Marine, et al.
Publicado: (2018)

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
por: Foloppe, Johann, et al.
Publicado: (2019)

Cowpox Virus: A New and Armed Oncolytic Poxvirus
por: Ricordel, Marine, et al.
Publicado: (2017)

Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
por: Béguin, Jérémy, et al.
Publicado: (2020)

Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs
por: Béguin, Jérémy, et al.
Publicado: (2021)

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
por: Gallardo, Franck, et al.
Publicado: (2020)

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment
por: Fend, Laetitia, et al.
Publicado: (2015)

Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
por: Béguin, Jérémy, et al.
Publicado: (2020)

Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus
por: Myers, Rachel, et al.
Publicado: (2016)

Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers
por: Downs-Canner, Stephanie, et al.
Publicado: (2016)

Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors
por: Béguin, Jérémy, et al.
Publicado: (2023)

High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
por: Delaunay, Tiphaine, et al.
Publicado: (2020)

Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus
por: Guo, Zong Sheng, et al.
Publicado: (2017)

Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
por: Heinrich, B, et al.
Publicado: (2017)

Oncolytic Vaccinia Virus Carrying Aphrocallistes vastus Lectin (oncoVV-AVL) Enhances Inflammatory Response in Hepatocellular Carcinoma Cells
por: Zheng, Xinnan, et al.
Publicado: (2022)

A cautionary note on the selectivity of oncolytic poxviruses
por: Tang, Bingtao, et al.
Publicado: (2019)

Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus
por: Cho, Euna, et al.
Publicado: (2018)

Theranostic Potential of Oncolytic Vaccinia Virus
por: Rojas, Juan J, et al.
Publicado: (2012)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1
por: Kleinpeter, Patricia, et al.
Publicado: (2019)

Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients
por: West, Emma J., et al.
Publicado: (2022)

Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
por: Samson, Adel, et al.
Publicado: (2022)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Oncolytic Vaccinia Virus in Lung Cancer Vaccines
por: Truong, Cao-Sang, et al.
Publicado: (2022)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
por: Kleinpeter, Patricia, et al.
Publicado: (2016)

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
por: Chen, Nanhai, et al.
Publicado: (2013)

Transcriptome Changes in Glioma Cells upon Infection with the Oncolytic Virus VV-GMCSF-Lact
por: Semenov, Dmitriy V., et al.
Publicado: (2023)

Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus
por: Burgess, Hannah M., et al.
Publicado: (2018)

Genetic Modifications That Expand Oncolytic Virus Potency
por: Cristi, Francisca, et al.
Publicado: (2022)

Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus
por: Arndt, William D., et al.
Publicado: (2016)

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
por: Guo, Zong Sheng, et al.
Publicado: (2019)

TRAIL Gene-Armed Oncolytic Poxvirus and Oxaliplatin Can Work Synergistically against Colorectal Cancer
por: Ziauddin, Mohammed F, et al.
Publicado: (2010)

The Combination of Immunosuppression and Carrier Cells Significantly Enhances the Efficacy of Oncolytic Poxvirus in the Pre-Immunized Host
por: Guo, Z. Sheng, et al.
Publicado: (2010)

Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model
por: Lee, J-H, et al.
Publicado: (2009)

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy
por: Liu, Zuqiang, et al.
Publicado: (2015)

Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses
por: Sampath, Padma, et al.
Publicado: (2013)

Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines
por: Lee, Hyun Ju, et al.
Publicado: (2011)

Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma
por: Deng, Lili, et al.
Publicado: (2022)

Antitumor activity of recombinant oncolytic vaccinia virus with human IL2
por: Liu, Liqiong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fdrf8s72uirqsbmm2jqdtobjed